


WHAT IS CLAIMED IS:

1. A polymorph of Compound A of structural formula:



Compound A

selected from Forms II, III and IV having the physical characteristics described in the following Table:

Form	II	III	IV
DSC extrapolated melting temperature onset	134-136°C	133°C	134° C
XRPD (peak positions, Cu K alpha)	5.6 9.4 10.7 17.6	10.5 16.1 22.4	8.7 15.2 17.1 19.5 21.7 23.5 23.6

2. A polymorph in accordance with Claim 1 which is Form IV.

3. A sesquihydrate of Form I having a DSC of about 134-136°C, peak m.p. 138°C, an XRPD pattern of 7.1, 9.7, 11.8, 15.5, 20.1, 22.7 and 24.1, and further containing approximately 1.5 mol water per mol of compound A.

4. A polymorph in accordance with Claim 1 which is Form IV.


5. A hemihydrate of Form IV in accordance with claim 4 containing 0.5 mol water per mol of compound A.

6. A polymorph in accordance with claim 1 which is Form III.

7. An amorphous form of Compound A in accordance with claim 1 obtained by cooling a molten sample of a crystalline form of Compound A.

8. A pharmaceutical composition comprised of a polymorph II, III or IV in accordance with claim 1 in combination with a pharmaceutically acceptable carrier.

9. A Form II polymorph of Compound A of structural formula:



Compound A

having a DSC extrapolated melting temperature onset of ~131°C, and XRPD peak positions, Cu K alpha of 5.6, 9.4, 10.7 and 17.6.